摘要
目的:研究肿瘤干细胞标志物ABCG2在卵巢黏液性肿瘤中的表达,并探讨其临床意义。方法:采用免疫组织化学PV-9000两步法检测ABCG2在22例卵巢黏液性囊腺瘤、19例卵巢交界性黏液性肿瘤和25例卵巢黏液性囊腺癌中的表达水平,分析其表达情况与卵巢黏液性肿瘤的临床病理特征的关系。结果:ABCG2在卵巢黏液性囊腺瘤、卵巢交界性黏液性肿瘤和卵巢黏液性囊腺癌中的阳性表达率分别为18.2%、47.4%、80.0%,3组间两两比较差异均有统计学意义(P<0.05)。在卵巢黏液性囊腺癌中,ABCG2在中低分化的阳性表达率高于高分化(P<0.05),III^IV期高于I^II期(P<0.05),但其表达与患者年龄无相关性(P>0.05)。结论:ABCG2可能参与卵巢黏液性肿瘤的发生、发展,其蛋白检测可能用于肿瘤恶性程度的判断。
Objective： To investigate the expression of cancer stem cell marker ABCG2 in ovarian mucinous tumors and its clinical significance. Mehtods： The expression of ABCG2 was detected by immunohistochemical PV-9000 2-step method in 22 cases of ovarian mucinous cystadenoma, 19 cases of ovarian borderline mucinous tumors and 25 cases of ovarian mucinous adenocarcinoma. The relationship between clinicopathologic characteristics was analyzed. Results： The positive expression rate of ABCG2 in ovarian mucinous cystadenoma, ovarian borderline mucinous tumors and ovarian mucinous adenocarcinoma was 18.2%, 47.4% and 80.0%, respectively. The expression level and positive expression rate of ABCG2 in benign mucinous cystadenoma and borderline mucinous tumor, in benign mucinous cystadenoma and mucinous adenocarcinoma, in mucinous borderline tumor and mucinous adenocarcinoma had statistical difference （P〈0.05）. The expression of ABCG2 in mucinous adenocarcinoma was significantly higher in stage III-IV than that in stage I-II （P〈0.05）, and it was significantly higher in moderate and poorly differentiated cancer tissues than in well differentiated cancer tissues （P〈0.05）, but not correlated with patient age （P〉0.05）. Conclusion： Expression of ABCG2 may participate in ovarian mucinous tumors during the progression from benign to malignant. And the protein detection may have referential significance in the estimation of tumor malignant degree.
出处
《温州医科大学学报》
CAS
2018年第1期46-48,共3页
Journal of Wenzhou Medical University
基金
温州市科技局科研基金资助项目(Y20140113)
